A Phase II, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Sfatey and Tolerability of X/T+X-EC vs. Placebo in Participants With Alzheimer's Disease Currently Treated With Lecanemab.
Latest Information Update: 15 Oct 2025
At a glance
- Drugs Lecanemab (Primary) ; Trospium chloride/xanomeline (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 15 Oct 2025 New trial record